このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Genscript Biotech 過去の業績

過去基準チェック /06

Genscript Biotechの収益は年間平均-23.2%の割合で減少していますが、 Life Sciences業界の収益は年間増加しています。収益は年間22.4% 25.7%割合で増加しています。

主要情報

-23.2%

収益成長率

-21.2%

EPS成長率

Life Sciences 業界の成長	41.4%
収益成長率	25.7%
株主資本利益率	-17.4%
ネット・マージン	-11.4%
前回の決算情報	31 Dec 2023

Recent updates

収支内訳

Genscript Biotech の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

SHSC:1548 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費	研究開発費
31 Dec 23	840	-95	393	433
30 Sep 23	773	-140	383	426
30 Jun 23	707	-185	374	420
31 Mar 23	667	-206	363	405
31 Dec 22	626	-227	352	390
30 Sep 22	598	-315	354	375
30 Jun 22	570	-403	356	361
31 Mar 22	530	-381	330	360
31 Dec 21	490	-359	303	358
30 Sep 21	483	-265	270	341
30 Jun 21	454	-183	235	323
31 Mar 21	422	-194	216	293
31 Dec 20	391	-205	197	263
30 Sep 20	354	-194	171	251
30 Jun 20	318	-183	146	239
31 Mar 20	296	-140	136	212
31 Dec 19	273	-97	126	186
30 Sep 19	257	-59	112	148
30 Jun 19	241	-22	98	109
31 Mar 19	236	0	89	92
31 Dec 18	231	21	79	74
30 Sep 18	216	24	72	58
30 Jun 18	201	27	65	41
31 Mar 18	177	26	56	30
31 Dec 17	153	26	47	18
30 Sep 17	139	27	48	11
30 Jun 17	125	28	49	5
31 Mar 17	120	27	50	2
31 Dec 16	115	26	51	0
30 Sep 16	107	26	50	0
30 Jun 16	99	25	48	0
31 Mar 16	93	21	47	0
31 Dec 15	87	18	46	0
30 Sep 15	82	13	43	0
30 Jun 15	78	8	39	0
31 Mar 15	74	7	38	0
31 Dec 14	70	6	37	0
31 Dec 13	60	6	29	0

質の高い収益: 1548は現在利益が出ていません。

利益率の向上: 1548は現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: 1548は利益が出ておらず、過去 5 年間で損失は年間23.2%の割合で増加しています。

成長の加速: 1548の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: 1548は利益が出ていないため、過去 1 年間の収益成長をLife Sciences業界 ( 0.7% ) と比較することは困難です。

株主資本利益率

高いROE: 1548は現在利益が出ていないため、自己資本利益率 ( -17.37% ) はマイナスです。

Genscript Biotech 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Full year 2023 earnings released: US$0.045 loss per share (vs US$0.11 loss in FY 2022)

Full year 2023 earnings released: US$0.045 loss per share (vs US$0.11 loss in FY 2022)

Genscript Biotech Corporation to Report Fiscal Year 2023 Final Results on Mar 09, 2024

First half 2023 earnings released: US$0.044 loss per share (vs US$0.063 loss in 1H 2022)

Genscript Biotech Corporation to Report First Half, 2023 Results on Aug 19, 2023

Full year 2022 earnings released: US$0.11 loss per share (vs US$0.17 loss in FY 2021)

Recent updates

Now 22% undervalued after recent price drop

GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications

Full year 2023 earnings released: US$0.045 loss per share (vs US$0.11 loss in FY 2022)

Now 25% undervalued after recent price drop

Insider recently sold HK$1.0m worth of stock

Genscript Biotech Corporation Announces Directorate Appointments and Change in Composition of Board Committee

Board Member recently sold HK$455k worth of stock

Genscript Biotech Corporation, Annual General Meeting, May 17, 2024

Full year 2023 earnings released: US$0.045 loss per share (vs US$0.11 loss in FY 2022)

Genscript Announces Appointment of Dr. David R. Liu to the Scientific Advisory Board

Genscript Biotech Corporation to Report Fiscal Year 2023 Final Results on Mar 09, 2024

New minor risk - Profitability

Executive Chairman recently sold HK$610k worth of stock

GenScript Biotech Corporation Expands its IVT mRNA Synthesis Portfolio with Addition of Customized Circular RNA and Lipid Nanoparticles Formulation Services

First half 2023 earnings released: US$0.044 loss per share (vs US$0.063 loss in 1H 2022)

Genscript Biotech Corporation to Report First Half, 2023 Results on Aug 19, 2023

Insider recently sold HK$1.4m worth of stock

Full year 2022 earnings released: US$0.11 loss per share (vs US$0.17 loss in FY 2021)

Now 24% undervalued

Now 20% undervalued

Genscript Biotech Corporation Announces Chief Executive Officer Changes

Genscript Biotech Corporation Announces Redesignation of Dr. Zhang Fangliang from A Non-Executive Director to an Executive Director with Effect from December 17, 2022

Less than half of directors are independent

First half 2022 earnings released: US$0.063 loss per share (vs US$0.046 loss in 1H 2021)

Genscript Biotech Corporation to Report First Half, 2022 Results on Aug 31, 2022

Genscript Biotech Corporation Provides Earnings Guidance for the Six Months Ended June 30, 2022

Genscript Biotech Corporation Announces Board Changes

Genscript Biotech Corporation Announces Board Changes

Full year 2021 earnings released: US$0.17 loss per share (vs US$0.11 loss in FY 2020)

Less than half of directors are independent

Genscript Biotech Corporation, Annual General Meeting, May 27, 2022

Genscript Biotech Corporation Provides Earnings Guidance for the Year Ended 31 December 2021

Board Member recently sold HK$2.1m worth of stock

First half 2021 earnings released: US$0.046 loss per share (vs US$0.06 loss in 1H 2020)

Key Executive recently sold HK$9.1m worth of stock

Duke-NUS Medical School and GenScript Biotech Corporation Announce Notice of Allowance for U.S. Patent Application for SARS-CoV-2 Surrogate Virus Neutralization Test

Hillhouse Capital Management, Ltd. completed the acquisition of 2.99% stake in Genscript Biotech Corporation (SEHK:1548) from GenScript Corporation.

Full year 2020 earnings released: US$0.11 loss per share (vs US$0.052 loss in FY 2019)

Full year 2020 earnings released

Genscript Biotech Corporation to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day high: HK$14.66

Genscript Probio and Neoletix Announce Successful Completion of 200-Liter Gmp Production Runs of Recombinant Coagulation Fviii Based on A Novel Production Technology

New 90-day low: HK$10.18

New 90-day low: HK$10.36

Genscript Biotech Corporation Announces Board and Director Changes

New 90-day low: HK$11.38

Co-Founder recently bought HK$3.7m worth of stock

First half earnings released

New 90-day low: HK$11.48

First half earnings released

New 90-day low - HK$14.96

Genscript Biotech Corporation to Report Q2, 2020 Results on Aug 29, 2020

Genscript Biotech Corporation Announces Management Changes Effective 2 August 2020

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06